Literature DB >> 28081777

Research advances in metabolism 2016.

Nikolaos Perakakis1, Olivia M Farr2, Dario Tuccinardi2, Jagriti Upadhyay3, Christos S Mantzoros3.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 28081777      PMCID： PMC5871911          DOI： 10.1016/j.metabol.2016.11.001

Source DB:  PubMed          Journal:  Metabolism        ISSN： 0026-0495            Impact factor:   8.694


× No keyword cloud information.
  111 in total

1.  Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.

Authors:  L Thomas; R Grempler; M Eckhardt; F Himmelsbach; A Sauer; T Klein; P Eickelmann; M Mark
Journal:  Diabetes Obes Metab       Date:  2011-11-13       Impact factor: 6.577

Review 2.  CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.

Authors:  M D Gorrell; V Gysbers; G W McCaughan
Journal:  Scand J Immunol       Date:  2001-09       Impact factor: 3.487

3.  Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity.

Authors:  Paula Walle; Markus Takkunen; Ville Männistö; Maija Vaittinen; Maria Lankinen; Vesa Kärjä; Pirjo Käkelä; Jyrki Ågren; Mika Tiainen; Ursula Schwab; Johanna Kuusisto; Markku Laakso; Jussi Pihlajamäki
Journal:  Metabolism       Date:  2016-01-23       Impact factor: 8.694

4.  Enhanced insulin sensitivity using electroacupuncture on bilateral Zusanli acupoints (ST 36) in rats.

Authors:  Shih-Liang Chang; Kuo-Juei Lin; Rong-Tsung Lin; Pei-Hsiu Hung; Jaung-Geng Lin; Juei-Tang Cheng
Journal:  Life Sci       Date:  2006-05-17       Impact factor: 5.037

Review 5.  Role of CD26/dipeptidyl peptidase IV in human T cell activation and function.

Authors:  Kei Ohnuma; Nozomu Takahashi; Tadanori Yamochi; Osamu Hosono; Nam H Dang; Chikao Morimoto
Journal:  Front Biosci       Date:  2008-01-01

6.  Activin A and follistatin in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios D Anastasilakis; Georgios Α Triantafyllou; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-07-25       Impact factor: 8.694

7.  Atorvastatin prevents advanced glycation end products (AGEs)-induced cardiac fibrosis via activating peroxisome proliferator-activated receptor gamma (PPAR-γ).

Authors:  Miao Chen; Hongwei Li; Guoxing Wang; Xuhua Shen; Shumei Zhao; Wen Su
Journal:  Metabolism       Date:  2015-11-27       Impact factor: 8.694

8.  (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.

Authors:  Leo Thomas; Matthias Eckhardt; Elke Langkopf; Moh Tadayyon; Frank Himmelsbach; Michael Mark
Journal:  J Pharmacol Exp Ther       Date:  2008-01-25       Impact factor: 4.030

Review 9.  Adiponectin as a potential biomarker of vascular disease.

Authors:  Mehrangiz Ebrahimi-Mamaeghani; Somayeh Mohammadi; Seyed Rafie Arefhosseini; Parviz Fallah; Zahra Bazi
Journal:  Vasc Health Risk Manag       Date:  2015-01-16

Review 10.  Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA.

Authors:  Simon C Dyall
Journal:  Front Aging Neurosci       Date:  2015-04-21       Impact factor: 5.750
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.